Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Hill

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Communications Medicine|January 20, 2026
5-methylcytosine and 5-hydroxymethylcytosine are synergistic biomarkers for early detection of colorectal cancerFabio Puddu, Annelie Johansson, Aurélie Modat, et al.
Scientific Reports|February 7, 2020
Integrative network modeling reveals mechanisms underlying T cell exhaustionHamid Bolouri, Mary Young, Joshua Beilke, et al.
European Journal of Cancer (Oxford, England : 1990)|January 27, 2022
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimensJonathan L Moore, Sacheen Kumar, Aida Santaolalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patientsHans-Joachim Schmoll, Thomas Cartwright, Josep Tabernero, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2013
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)Gary Middleton, Sarah Brown, Catherine Lowe, et al.
Cancer Research|May 12, 2025
Systemic Inactivation of TREX1 Induces Selective Inflammation of the Tumor Microenvironment and Invigorated T Cell-Mediated Tumor ControlEmilija Marinkovic, Minyi Chen, Nadja Schubert, et al.
The Lancet. Oncology|June 4, 2013
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialMatthew T Seymour, Sarah R Brown, Gary Middleton, et al.
Clinical Colorectal Cancer|October 26, 2021
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic FactorsChara Stavraka, Athanasios Pouptsis, Alicja Synowiec, et al.
Journal of Medicinal Chemistry|November 27, 2023
Identification of Small Molecule Inhibitors and Ligand Directed Degraders of Calcium/Calmodulin Dependent Protein Kinase Kinase 1 and 2 (CaMKK1/2)Young Chen, Brandon Whitefield, Erin Nevius, et al.
The Journal of Pathology|November 15, 2023
Genetic and immune landscape evolution in MMR-deficient colorectal cancerBenjamin R Challoner, Andrew Woolston, David Lau, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Communications Medicine|January 20, 2026
5-methylcytosine and 5-hydroxymethylcytosine are synergistic biomarkers for early detection of colorectal cancerFabio Puddu, Annelie Johansson, Aurélie Modat, et al.
Scientific Reports|February 7, 2020
Integrative network modeling reveals mechanisms underlying T cell exhaustionHamid Bolouri, Mary Young, Joshua Beilke, et al.
European Journal of Cancer (Oxford, England : 1990)|January 27, 2022
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimensJonathan L Moore, Sacheen Kumar, Aida Santaolalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patientsHans-Joachim Schmoll, Thomas Cartwright, Josep Tabernero, et al.
European Journal of Cancer (Oxford, England : 1990)|August 20, 2013
A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)Gary Middleton, Sarah Brown, Catherine Lowe, et al.
Cancer Research|May 12, 2025
Systemic Inactivation of TREX1 Induces Selective Inflammation of the Tumor Microenvironment and Invigorated T Cell-Mediated Tumor ControlEmilija Marinkovic, Minyi Chen, Nadja Schubert, et al.
The Lancet. Oncology|June 4, 2013
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trialMatthew T Seymour, Sarah R Brown, Gary Middleton, et al.
Clinical Colorectal Cancer|October 26, 2021
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic FactorsChara Stavraka, Athanasios Pouptsis, Alicja Synowiec, et al.
Journal of Medicinal Chemistry|November 27, 2023
Identification of Small Molecule Inhibitors and Ligand Directed Degraders of Calcium/Calmodulin Dependent Protein Kinase Kinase 1 and 2 (CaMKK1/2)Young Chen, Brandon Whitefield, Erin Nevius, et al.
The Journal of Pathology|November 15, 2023
Genetic and immune landscape evolution in MMR-deficient colorectal cancerBenjamin R Challoner, Andrew Woolston, David Lau, et al.
Pageof 6